According to the cooperation agreement, leveraging Sanyou's world-leading core technology platform for integrated R&D and preclinical development of innovative biological drugs, along with a world-class "super-trillion innovative biologics discovery platform", a strong collaboration will be formed with Sinorda's rich experience in preclinical and clinical oncology immunotherapy. This collaboration aims to jointly advance the R&D of the product pipeline through cooperative efforts.

Pingsheng Hu, CEO of Sinorda, stated, "Sinorda focuses on the research and development of innovative drug and industrialization of oncology immunotherapy. Our partnership with Sanyou merges our strengths, accelerating the drug development process and transforming innovative achievements into reality faster. This collaboration improves treatment choices for patients. With this shared vision, we can work together to advance innovative drug products and contribute to human health."

Guojun Lang, CEO of Sanyou, commented, "We're truely honored to establish a strategic cooperation with Sinorda. Their strong scientific and medical expertise, robust clinical capabilities, and extensive experience in industrial collaboration perfectly align with Sanyou. Both Sanyou and Sinorda share the common goal of using biopharmaceutical technology to enhance human health. Our combined strengths and robust collaboration will open new opportunities and forge a pioneering model of cooperation between innovative drug research and development services and pharmaceutical enterprises. Together, we are committed to delivering positive outcomes for patients worldwide."